Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AV2
- Development stage
- Phase 2
- Lead developer
- Cesa Alliance
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
AV2 is an investigational topical antiviral cervical spray composed of natural essential-oil constituents carvone, eugenol, geraniol, and nerolidol in olive oil. It was developed for human papillomavirus-associated cervical lesions and cervical HPV infection. Its proposed mechanism is extracellular viral inactivation before cellular entry, but no validated molecular target has been established. AV2 has been evaluated in placebo-controlled clinical studies, including a published phase 3 trial in women with HPV-associated cervical lesions. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6529824/))
- Brand names
- AV2AV-2AV 2
- Other names
- Antiviral 2Antiviral2Antiviral-2
Beyond the preview
Go deeper on AV2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AV2.